Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 4, Pages 484
Publisher
MDPI AG
Online
2019-04-05
DOI
10.3390/cancers11040484
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- P-161FOLFIRINOX versus gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer: a single-center cohort study
- (2018) I Cho et al. ANNALS OF ONCOLOGY
- FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma
- (2018) Mashaal Dhir et al. ANNALS OF SURGICAL ONCOLOGY
- Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer
- (2018) Junko Tahara et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable or metastatic pancreatic ductal adenocarcinoma
- (2018) Susanna Hegewisch-Becker et al. INTERNATIONAL JOURNAL OF CANCER
- Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis
- (2018) Jihoon Kang et al. INVESTIGATIONAL NEW DRUGS
- The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis
- (2018) Hongxuan Tong et al. Scientific Reports
- Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States
- (2018) Sunnie Kim et al. ADVANCES IN THERAPY
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
- (2018) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer
- (2018) Moon Jae Chung et al. World Journal of Gastrointestinal Oncology
- Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX
- (2017) George P. Kim et al. Expert Review of Clinical Pharmacology
- Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX
- (2017) Ali McBride et al. Expert Review of Clinical Pharmacology
- Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting
- (2017) Fadi S Braiteh et al. Cancer Management and Research
- APACT: Phase III randomized trial of adjuvant treatment with nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected pancreatic cancer (PC).
- (2016) Margaret A. Tempero et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcomes in metastatic pancreatic adenocarcinoma (MPAC) patients treated with FOLFIRINOX (FFX)/FOLFOX(FX) and gemcitabine + nab-paclitaxel (NabG).
- (2016) Shannon Leah Schmidt et al. JOURNAL OF CLINICAL ONCOLOGY
- Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- (2016) Davendra P.S. Sohal et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRINOX-Based Neoadjuvant Therapy in Borderline Resectable or Unresectable Pancreatic Cancer
- (2015) Fausto Petrelli et al. PANCREAS
- Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis
- (2014) Gillian K Gresham et al. BMC CANCER
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
- (2010) Andreas Stang EUROPEAN JOURNAL OF EPIDEMIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started